Microbot Medical (MBOT) Stock Falls on Short Report

MBOT Shares Decline on Bearish Research

Microbot Medical Inc. (NASDAQ:MBOT) shares experienced a significant 7.8% drop on Thursday. The decline followed the publication of a critical short report by White Diamond Research, which raised serious questions about the commercial potential of the company's LIBERTY Endovascular Robotic System.

Overview of the Report's Findings

White Diamond Research initiated a short position on MBOT and set a price target of $1. The report's conclusions were based on interviews with surgeons who have used the LIBERTY system. Key concerns highlighted include the device adding $3,000 to $4,000 in costs per procedure without a clear reimbursement pathway. Surgeons also noted that the system increases procedure times and offers no discernible accuracy advantage over traditional manual techniques.

Impact and Market Viability Concerns

The report underscores several practical and economic challenges. It revealed that the LIBERTY system is only compatible with .014" guidewires, whereas the industry standard for most peripheral vascular procedures is .018". Furthermore, the entire system, including its robotic components, is designed for single-use and is disposed of after each procedure. White Diamond also pointed out that the device lacks a specific reimbursement code and fails to qualify for New Technology Add-on Payment status, citing a lack of substantial clinical benefits over existing methods.

Conclusion and Outlook

The short report from White Diamond Research has cast significant doubt on the adoption rate and financial viability of the LIBERTY system. The claims regarding high costs, operational inefficiencies, and lack of reimbursement have fueled negative investor sentiment, leading to the sharp decline in stock price. The market will be closely watching for Microbot Medical's response to these allegations and any future data that could validate the system's clinical and economic value.

FAQ

Q: Why did Microbot Medical's stock fall sharply?
A: The stock fell 7.8% after White Diamond Research released a bearish short report questioning the commercial viability and practicality of its LIBERTY robotic system.

Q: What are the main criticisms against the LIBERTY system?
A: The main criticisms include high procedural costs with no reimbursement, longer operation times, limited guidewire compatibility, and a lack of significant clinical advantages over manual methods.

Source: Investing.com